Therapeutic Applications of Botulinum Neurotoxins in Head and Neck Disorders

Overview

Journal Saudi Dent J

Specialty Dentistry

Date 2014 Dec 30

PMID 25544809

Citations 4

Authors

Ahmad Alshadwi

Mohammed Nadershah

Timothy Osborn

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this article is to review the mechanism of action, physiological effects, and therapeutic applications of botulinum neurotoxins in the head and neck area.

Study Design: An extensive literature search was performed using keywords. The resulting articles were analyzed for relevance in four areas: overview on botulinum neurotoxins, the role of botulinum neurotoxins in the management of salivary secretory disorders, the role of botulinum neurotoxins in the management of facial pain, and the role of botulinum neurotoxins in head and neck movement disorders. Institutional review board approval was not needed due the nature of the study.

Results: Botulinum neurotoxin therapy was demonstrated to be a valuable alternative to conventional medical therapy for many conditions affecting the head and neck area in terms of morbidly, mortality, and patient satisfaction with treatment outcomes.

Conclusion: Botulinum neurotoxin therapy provides viable alternatives to traditional treatment modalities for some conditions affecting the head and neck region that have neurological components. This therapy can overcome some of the morbidities associated with conventional therapy. More research is needed to determine the ideal doses of botulinum neurotoxin to treat different diseases affecting the head and neck regions.

Citing Articles

A Systematic Review and Comparative Analysis of Botox Treatment in Aesthetic and Therapeutic Applications: Advantages, Disadvantages, and Patient Outcomes.

Meretsky C, Umali J, Schiuma A Cureus. 2024; 16(8):e67961.

PMID: 39328645 PMC: 11427080. DOI: 10.7759/cureus.67961.

Clinical and electromyographic evaluation of botulinum toxin type A in the treatment of gummy smile: A prospective clinical study.

Mate P, Nilesh K, Joshi A, Panda A J Dent Res Dent Clin Dent Prospects. 2021; 15(2):122-128.

PMID: 34386184 PMC: 8346717. DOI: 10.34172/joddd.2021.021.

Alternative Methods for Testing Botulinum Toxin: Current Status and Future Perspectives.

Nepal M, Jeong T Biomol Ther (Seoul). 2020; 28(4):302-310.

PMID: 32126735 PMC: 7327137. DOI: 10.4062/biomolther.2019.200.

Botulinum Neurotoxin-A Injected Intrastriatally into Hemiparkinsonian Rats Improves the Initiation Time for Left and Right Forelimbs in Both Forehand and Backhand Directions.

Antipova V, Holzmann C, Hawlitschka A, Wree A Int J Mol Sci. 2019; 20(4).

PMID: 30823527 PMC: 6412467. DOI: 10.3390/ijms20040992.

References

Goldman J, Comella C . Treatment of dystonia. Clin Neuropharmacol. 2003; 26(2):102-8. DOI: 10.1097/00002826-200303000-00010. View

Drobik C, Laskawi R . Frey's syndrome: treatment with botulinum toxin. Acta Otolaryngol. 1995; 115(3):459-61. DOI: 10.3109/00016489509139348. View

Soares A, Andriolo R, Atallah A, da Silva E . Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev. 2012; (4):CD007533. DOI: 10.1002/14651858.CD007533.pub2. View

Katusic S, Williams D, Beard C, Bergstralh E, Kurland L . Incidence and clinical features of glossopharyngeal neuralgia, Rochester, Minnesota, 1945-1984. Neuroepidemiology. 1991; 10(5-6):266-75. DOI: 10.1159/000110283. View

Vartanian A, Dayan S . Complications of botulinum toxin A use in facial rejuvenation. Facial Plast Surg Clin North Am. 2004; 11(4):483-92. DOI: 10.1016/S1064-7406(03)00070-1. View

Graboski C, Gray D, Burnham R . Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: a randomised double blind crossover study. Pain. 2005; 118(1-2):170-5. DOI: 10.1016/j.pain.2005.08.012. View

Capaccio P, Torretta S, Osio M, Minorati D, Ottaviani F, Sambataro G . Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders. Am J Otolaryngol. 2008; 29(5):333-8. DOI: 10.1016/j.amjoto.2007.10.003. View

Capaccio P, Cuccarini V, Benicchio V, Minorati D, Spadari F, Ottaviani F . Treatment of iatrogenic submandibular sialocele with botulinum toxin. Case report. Br J Oral Maxillofac Surg. 2006; 45(5):415-7. DOI: 10.1016/j.bjoms.2006.02.001. View

Langevin P, Peloso P, Lowcock J, Nolan M, Weber J, Gross A . Botulinum toxin for subacute/chronic neck pain. Cochrane Database Syst Rev. 2011; (7):CD008626. DOI: 10.1002/14651858.CD008626.pub2. View

10.

Blanchet P, Rompre P, Lavigne G, Lamarche C . Oral dyskinesia: a clinical overview. Int J Prosthodont. 2005; 18(1):10-9. View

11.

Aurora S, Dodick D, Turkel C, DeGryse R, Silberstein S, Lipton R . OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30(7):793-803. DOI: 10.1177/0333102410364676. View

12.

Thakker M, Rubin P . Pharmacology and clinical applications of botulinum toxins A and B. Int Ophthalmol Clin. 2004; 44(3):147-63. DOI: 10.1097/00004397-200404430-00014. View

13.

Lam S . The basic science of botulinum toxin. Facial Plast Surg Clin North Am. 2004; 11(4):431-8. DOI: 10.1016/S1064-7406(03)00073-7. View

14.

Kurtoglu C, Gur O, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H . Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg. 2008; 66(8):1644-51. DOI: 10.1016/j.joms.2008.03.008. View

15.

Marchese-Ragona R, Galzignato P, Marioni G, Guarda-Nardini L, Tregnaghi A, Restivo D . Endoscopic diagnosis of rhino-parotid fistula and successful treatment with botulinum toxin. Laryngoscope. 2005; 115(11):2062-4. DOI: 10.1097/00005537-200511000-00030. View

16.

Manolopoulos L, Vlastarakos P, Georgiou L, Giotakis I, Loizos A, Nikolopoulos T . Myofascial pain syndromes in the maxillofacial area: a common but underdiagnosed cause of head and neck pain. Int J Oral Maxillofac Surg. 2008; 37(11):975-84. DOI: 10.1016/j.ijom.2008.04.023. View

17.

Ashkenazi A, Blumenfeld A . OnabotulinumtoxinA for the treatment of headache. Headache. 2013; 53 Suppl 2:54-61. DOI: 10.1111/head.12185. View

18.

Erbguth F, Naumann M . Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison". Neurology. 1999; 53(8):1850-3. DOI: 10.1212/wnl.53.8.1850. View

19.

De Andres J, Cerda-Olmedo G, Valia J, Monsalve V, Lopez-Alarcon , Minguez A . Use of botulinum toxin in the treatment of chronic myofascial pain. Clin J Pain. 2003; 19(4):269-75. DOI: 10.1097/00002508-200307000-00011. View

20.

Gartlan M, Hoffman H . Crystalline preparation of botulinum toxin type A (Botox): degradation in potency with storage. Otolaryngol Head Neck Surg. 1993; 108(2):135-40. DOI: 10.1177/019459989310800205. View